levetiracetam + placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Tardive Dyskinesia
Conditions
Tardive Dyskinesia
Trial Timeline
— → —
NCT ID
NCT00291213About levetiracetam + placebo
levetiracetam + placebo is a phase 3 stage product being developed by UCB for Tardive Dyskinesia. The current trial status is completed. This product is registered under clinical trial identifier NCT00291213. Target conditions include Tardive Dyskinesia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00291213 | Phase 3 | Completed |
| NCT01228747 | Phase 3 | Completed |
| NCT00566046 | Phase 3 | Terminated |
| NCT00291733 | Phase 2 | UNKNOWN |
| NCT00254657 | Pre-clinical | Completed |
| NCT00615615 | Phase 3 | Completed |
Competing Products
13 competing products in Tardive Dyskinesia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Sarizotan | Merck | Pre-clinical | 23 |
| Valbenazine | Neurocrine Biosciences | Phase 1 | 30 |
| Valbenazine Oral Capsule | Neurocrine Biosciences | Approved | 82 |
| NBI-98854 + NBI-98854 + Placebo | Neurocrine Biosciences | Phase 2 | 49 |
| NBI-98854 + NBI-98854 + Placebo | Neurocrine Biosciences | Phase 2 | 49 |
| NBI-98854 | Neurocrine Biosciences | Phase 3 | 74 |
| Valbenazine + Placebo oral capsule | Neurocrine Biosciences | Approved | 82 |
| NBI-98854 | Neurocrine Biosciences | Phase 2 | 49 |
| NBI-98854 + Placebo | Neurocrine Biosciences | Phase 3 | 74 |
| Valbenazine | Neurocrine Biosciences | Phase 3 | 74 |
| NBI-98854 + NBI-98854 + Placebo | Neurocrine Biosciences | Phase 2 | 49 |
| Valbenazine + Placebo oral capsule | Neurocrine Biosciences | Approved | 82 |
| NBI-1065890 + Placebo | Neurocrine Biosciences | Phase 2 | 49 |